852A

852A is a synthetic imidazoquinoline Toll-like receptor 7 (TLR7) agonist with immunostimulating and potential antitumor activities. It works by binding to and activating TLR7, thereby stimulating plasmacytoid dendritic cells through the TLR7-MyD88-dependent signaling pathway. This activation results in secretion of interferon alpha, production of proinflammatory cytokines, upregulation of co-stimulatory molecules, and enhanced T and B-cell stimulatory responses. Originally developed by 3M Drug Delivery Systems (now Kindeva Drug Delivery), it has been investigated for various cancers including melanoma, breast cancer, ovarian cancer, and cervical cancer.

Other names

N-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamideN-(4-(4-Amino-2-ethyl-imidazo(4,5-c)quinolin-1-yl)butyl)methanesulfonamidetoll-like receptor 7 agonist 852A